Detail akcie Danaher Corp online

Business Summary: Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Financial Summary: BRIEF: For the three months ended 28 March 2025, Danaher Corp revenues decreased 1% to $5.74B. Net income decreased 12% to $954M. Revenues reflect Diagnostics segment decrease of 3% to $2.45B, Life Sciences segment decrease of 4% to $1.68B. Net income also reflects Diagnostics segment income decrease of 13% to $718M, Life Sciences segment income decrease of 14% to $201M, Other segment loss increase of 10% to $86M.